12,372 trials
Infections, Streptococcal
Primary: Number of Subjects With Grade 3 Adverse Events (Solicited and Unsolicited) — 3; 1; 2 Participants
Hunter Syndrome
Primary: Change From Baseline in the Differential Ability Scales, Second Edition (DAS-II) General Conceptual Ability (GCA) Standard Score at Week 52 — -7.4; -4.4 Score on a scale…
Multiple Myeloma
Primary: Progression Free Survival — 7.6; 11.2 months — p=0.0014
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS) — 11.4; 10.6 months — p== 0.0721
Idiopathic Intracranial Hypertension
Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05
Spondylitis, Ankylosing
Primary: Number of Participants With 20% Improvement in the Assessment of Spondyloarthritis International Society Criteria Scale / ASAS 20 Response — 43; 46; 28; 31 Participants…
Postmenopausal Women With Osteoporosis
Primary: Percentage of Participants With New Vertebral Fractures Through Month 24 — 8.0; 4.1 percentage of participants — p=<0.001
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -0.643; 0.415 Percentage of HbA1c — p=<0.001
Urinary Tract Infection Complicated · Acute Pyelonephritis · Hospital Acquired Bacterial Pneumonia
Primary: Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success…
Urinary Tract Infection Symptomatic · Acute Pyelonephritis · Urinary Tract Infection Complicated
Primary: Number of Patients With an Overall Success — 119; 97 Participants
cUTI
Primary: Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit — 180; 202; 100; 91 Participants
Plaque Psoriasis
Primary: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 — 10; 3 Participants — p=0.0745
Acute Lymphoblastic Leukemia · Acute Undifferentiated Leukemia · Childhood T Acute Lymphoblastic Leukemia
Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2 — 5.52; 5.53; -1.41; -1.22 units on a scale
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) — -1.00; -0.89; -0.20 Percentage A1C — p=<0.001